Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


EGFR ligands dictate tumour suppression

EGFR is an oncogene that is frequently amplified in glioblastoma. A new study suggests a tumour-suppressive role of EGFR in EGFR-amplified glioblastoma regulated by ligand abundance. Increased EGFR ligand in EGFR-amplified glioblastoma suppresses invasion by upregulating BIN3 and inhibiting activation of Rho GTPases.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: EGFR directs two distinct and mutually exclusive signalling pathways: constitutive signalling and ligand-activated signalling.


  1. Louis, D. N. et al. Neuro Oncol. 23, 1231–1251 (2021).

    CAS  Article  Google Scholar 

  2. Dirks, P. B. et al. Clin. Cancer Res. 26, 2457–2460 (2020).

    Article  Google Scholar 

  3. Brennan, C. W. et al. Cell 155, 462–477 (2013).

    CAS  Article  Google Scholar 

  4. Fan, Q. W. et al. Cancer Cell 24, 438–449 (2013).

    CAS  Article  Google Scholar 

  5. Chakraborty, S. et al. Nat. Commun. 5, 5811 (2014).

    CAS  Article  Google Scholar 

  6. Singh, B. et al. F1000 Res. (2016).

    Article  Google Scholar 

  7. Hu, C. et al. Nature 602, 518–522 (2022).

    CAS  Article  Google Scholar 

  8. Guo, G. et al. Nat. Cell Biol. (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  9. An, Z. et al. Oncogene 37, 1561–1575 (2018).

    CAS  Article  Google Scholar 

  10. de Vries, N. A. et al. Invest. New Drugs 30, 443–449 (2012).

    CAS  Article  Google Scholar 

  11. Barkovich, K. J. et al. Cancer Discov. 2, 450–457 (2012).

    CAS  Article  Google Scholar 

  12. Ramnarain, D. B. et al. Cancer Res. 66, 867–874 (2006).

    CAS  Article  Google Scholar 

  13. Prendergast, G. C. et al. Biochim. Biophys. Acta 1796, 25–36 (2009).

    Google Scholar 

  14. Murray, D. W. et al. Br. J. Cancer 110, 1307–1315 (2014).

    CAS  Article  Google Scholar 

  15. Ramnarain, D. B. et al. Cancer Res. 66, 867–874 (2006).

    CAS  Article  Google Scholar 

  16. Le Rhun, E. et al. Cancer Treat. Rev. 80, 101896 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to William A. Weiss.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Beytagh, M.C., Weiss, W.A. EGFR ligands dictate tumour suppression. Nat Cell Biol 24, 1189–1191 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing